PE20030329A1 - Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo - Google Patents

Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo

Info

Publication number
PE20030329A1
PE20030329A1 PE2002000719A PE2002000719A PE20030329A1 PE 20030329 A1 PE20030329 A1 PE 20030329A1 PE 2002000719 A PE2002000719 A PE 2002000719A PE 2002000719 A PE2002000719 A PE 2002000719A PE 20030329 A1 PE20030329 A1 PE 20030329A1
Authority
PE
Peru
Prior art keywords
phenyl
amino
methyl
ring
link
Prior art date
Application number
PE2002000719A
Other languages
English (en)
Inventor
Mitsuru Shiraishi
Masanori Baba
Katsuji Aikawa
Naoyuki Kanzaki
Masaki Seto
Yuki Iizawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PE20030329A1 publication Critical patent/PE20030329A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A COMPUESTOS BICICLICOS DE FORMULA I DONDE R1 ES UN ANILLO DE 5-6 MIEMBROS; X1 ES UN ENLACE, CADENA DE 1-4 ATOMOS; ANILLO A DE 5-6 MIEMBROS; ANILLO B DE 8-10 MIEMBROS; E1 Y E4 SON C, N; E3, E2 SON C, N, S, O; a Y b ES ENLACE SIMPLE O DOBLE; X2 ES CADENA DE 1-4 MIEMBROS; Z1 ES ENLACE, GRUPO CICLICO BIVALENTE; Z2 ES ENLACE; R2 ES AMINO, HETEROCICLO, PR5R6(O)k, AMIDINO, GUANIDINO; k ES 0-1; R5 Y R6 SON HIDROCARBURO, HIDROXI, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 8-[4-(2-BUTOXIETOXI)-FENIL]-1-ISOBUTIL-N-[4-[[N-METIL-N-(TETRAHIDROPIRAN-4-IL)AMINO]METIL]FENIL]-1,2,3,4-TETRAHIDRO-1-BENZAZOCIN-5-CARBOXAMIDA; (S)-1-ISOBUTIL-8-[4-(2-PROPOXIETOXI)FENIL]-N-4-[[(1-PROPIL-1H-IMIDAZOL-5-IL)METIL]SULFINIL]FENIL]-1,2,3,4-TETRAHIDRO-1-BENZAZOCIN-5-CARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION; A UNA COMPOSICION QUE COMPRENDE ADEMAS INHIBIDOR DE PROTEASA COMO SAQUINAVIR, ZITONAVIR, INDINAVIR, AMPRENAVIR, NELFINAVIR, INHIBIDOR DE TRANSCRIPTASA INVERSA COMO ZIDOVUDINA, DIDANOSINA, ZALCITABINA, LAMIVUDINA, ENTRE OTROS. LOS COMPUESTOS SON ANTAGONISTAS DE CCR5 Y PUEDEN SER UTILES PARA TRATAR ENFERMEDADES INFECCIOSAS DE VIH, ARTRITIS REUMATOIDEA CRONICA, ENFERMEDAD AUTOINMUNE, ENFERMEDADES ALERGICAS, TRASTORNO CELULAR CEREBRAL ISQUEMICO, INFARTO CARDIACO, NEFRITIS CRONICA, ARTERIOESCLEROSIS
PE2002000719A 2001-08-08 2002-08-07 Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo PE20030329A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12

Publications (1)

Publication Number Publication Date
PE20030329A1 true PE20030329A1 (es) 2003-05-12

Family

ID=26620186

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000719A PE20030329A1 (es) 2001-08-08 2002-08-07 Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo

Country Status (14)

Country Link
US (7) US7371772B2 (es)
EP (3) EP1423376B1 (es)
JP (4) JP4316203B2 (es)
AR (1) AR034985A1 (es)
AT (2) ATE539062T1 (es)
AU (1) AU2002328092A1 (es)
CA (2) CA2607992A1 (es)
DE (1) DE60235632D1 (es)
DK (2) DK1423376T3 (es)
ES (2) ES2376855T3 (es)
HK (1) HK1142886A1 (es)
PE (1) PE20030329A1 (es)
PT (2) PT2206702E (es)
WO (1) WO2003014105A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1423376T3 (da) 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
WO2003076411A1 (fr) * 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
US20060178359A1 (en) * 2003-02-07 2006-08-10 Mitsuru Shiraishi Tricyclic compound, process for producing the same, and use
US7288654B2 (en) 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
EP1728504B1 (en) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
AU2009305619B2 (en) * 2008-10-17 2012-06-21 Invasc Therapeutics, Inc. Compositions and methods for treatment of renin-angiotensin aldosterone system (RAAS)-related disorders
EA201890254A3 (ru) 2009-11-27 2019-02-28 Джензим Корпорэйшн Ингибиторы глюкозилцерамидсинтазы
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP3119401A4 (en) * 2014-03-21 2017-12-13 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
MA39991A (fr) * 2014-06-02 2015-12-10 Tobira Therapeutics Inc Cénicriviroc pour le traitement de l'infection à vih-2
JP2017526713A (ja) 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
MX2017008280A (es) 2014-12-23 2017-12-07 Tobira Therapeutics Inc Proceso para elaborar cenicriviroc y analogos relacionados.
CN107405403B (zh) 2015-02-10 2021-04-20 妥必徕疗治公司 用于治疗纤维化和腹膜炎的塞尼克韦罗
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
WO2017223155A1 (en) 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
BR112019003987A2 (pt) * 2016-08-31 2019-05-28 Tobira Therapeutics Inc formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc
WO2018103757A1 (zh) 2016-12-09 2018-06-14 广东众生药业股份有限公司 作为ccr2/ccr5受体拮抗剂的联苯化合物
EP3585384A1 (en) 2017-02-24 2020-01-01 Genfit Pharmaceutical compositions for combination therapy
CN111630047B (zh) * 2018-02-02 2023-05-23 四川科伦博泰生物医药股份有限公司 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
JP7292588B2 (ja) * 2019-06-24 2023-06-19 无錫▲りん▼方生物医薬科技有限公司 Ｃｃｒ２／ｃｃｒ５アンタゴニストとしてのヘテロシクロアルキル系化合物
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US20230183221A1 (en) 2020-05-22 2023-06-15 Medshine Discovery Inc. Pyridine derivative and application thereof
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
EP0769015B1 (en) 1994-07-04 2001-03-14 Takeda Chemical Industries, Ltd. Phosphonic acid compounds, their production and use
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
CN1152686C (zh) 1997-10-20 2004-06-09 大日本制药株式会社 稳定化药用组合物
CA2304959A1 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
AU5301599A (en) * 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
CA2353635A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
EP1172097B1 (en) 1999-04-12 2004-09-08 Shionogi & Co., Ltd. Process for producing medicinal composition of a basic hydrophobic medicinal compound
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (en) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd METHOD FOR PRODUCING 2,3-DIHYDROAZEPINE DERIVATIVES
DK1423376T3 (da) * 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
WO2003076411A1 (fr) 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
EP1728504B1 (en) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
WO2008030853A2 (en) 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
US9562038B2 (en) 2010-11-18 2017-02-07 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
EP2723360B1 (en) 2011-06-27 2017-05-31 Université Pierre et Marie Curie (Paris 6) Ccr2 antagonist peptides
MY180145A (en) 2013-05-15 2020-11-23 Tobira Therapeutics Inc Cenicriviroc compositions and methods of making and using the same
EP3119401A4 (en) 2014-03-21 2017-12-13 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
MX2017008280A (es) 2014-12-23 2017-12-07 Tobira Therapeutics Inc Proceso para elaborar cenicriviroc y analogos relacionados.
CN107405403B (zh) 2015-02-10 2021-04-20 妥必徕疗治公司 用于治疗纤维化和腹膜炎的塞尼克韦罗

Also Published As

Publication number Publication date
US20080161287A1 (en) 2008-07-03
EP1889839B1 (en) 2013-11-06
ES2376855T3 (es) 2012-03-20
US20090030032A1 (en) 2009-01-29
US20040259876A1 (en) 2004-12-23
US8362058B2 (en) 2013-01-29
PT2206702E (pt) 2012-02-03
CA2607992A1 (en) 2003-02-20
CA2459172A1 (en) 2003-02-20
EP2206702B1 (en) 2011-12-28
JP4358851B2 (ja) 2009-11-04
EP2206702A1 (en) 2010-07-14
WO2003014105A9 (en) 2003-11-20
EP1423376B1 (en) 2010-03-10
EP1889839A1 (en) 2008-02-20
EP1423376A1 (en) 2004-06-02
JP2013136629A (ja) 2013-07-11
US8183273B2 (en) 2012-05-22
CA2459172C (en) 2011-07-05
PT1423376E (pt) 2010-04-12
US20190038604A1 (en) 2019-02-07
ATE539062T1 (de) 2012-01-15
US10045968B2 (en) 2018-08-14
JP5275148B2 (ja) 2013-08-28
WO2003014105A1 (en) 2003-02-20
DE60235632D1 (de) 2010-04-22
DK2206702T3 (da) 2012-02-13
DK1423376T3 (da) 2010-06-28
US20160008326A1 (en) 2016-01-14
AR034985A1 (es) 2004-03-24
JP2007084578A (ja) 2007-04-05
HK1142886A1 (en) 2010-12-17
US8741943B2 (en) 2014-06-03
AU2002328092A1 (en) 2003-02-24
US20200297700A1 (en) 2020-09-24
JP2003335776A (ja) 2003-11-28
ATE460406T1 (de) 2010-03-15
JP4316203B2 (ja) 2009-08-19
ES2339340T3 (es) 2010-05-19
US20120232028A1 (en) 2012-09-13
US7371772B2 (en) 2008-05-13
JP2009209154A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
PE20030329A1 (es) Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
BR112021022796A2 (pt) Inibidores de inflamassoma de nlrp3
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
BRPI0514692A (pt) inibidores do receptor sigma
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
CL2023002276A1 (es) Inhibidores de cdk y métodos de uso de estos
EA200401437A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам
BRPI0606437A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
BR0014602A (pt) Hexaidrofluoro'2,3-bifuran-3-il-n-{3'(1,3-benzodioxol- 5ilsulfonil)(isobutil)amino-1 -benzil-2-hidroxipropil}carbamato como inibidor da protease retroviral
BRPI0519792A2 (pt) antagonistas do receptor 5-ht7
PE20231073A1 (es) Inhibidores de pi3k y metodos de uso de los mismos
NO20072269L (no) Arylsulfonamid peri-substituerte bicykliske forbindelser for okklusiv arteriesykdom
ECSP20068210A (es) Moduladores calpaína y usos terapéuticos de los mismos
BRPI0409928B8 (pt) composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
AR057526A1 (es) Metodos para la produccion de composiciones oftalmicas oxidativamente estables
AR053177A1 (es) Composicion de jabon
MX2007001992A (es) Antagonistas del receptor 5-ht7.
CO2023014807A2 (es) Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
EA202191150A1 (ru) Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции
ATE536101T1 (de) Behandlung heilmittelresistenter proliferativer erkrankungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal